Render Target: SSR
Render Timestamp: 2024-11-14T22:33:06.105Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-06-25 22:07:07.097
Product last modified at: 2024-06-29T08:00:12.859Z
1% for the planet logo
PDP - Template Name: ELISA Kit
PDP - Template ID: *******bd382c2

PathScan® RP CRBN Sandwich ELISA Kit #43562

Filter:
  • ELISA

    Supporting Data

    REACTIVITY H M R
    Application Key:
    • ELISA-ELISA 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Description

    The rapid protocol (RP) PathScan® RP CRBN Sandwich ELISA Kit is a solid phase sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of CRBN protein in a reduced assay time of 1.5 hours. Incubation of cell lysates and detection antibody on the coated microwell plate forms a sandwich with CRBN in a single step. The plate is then extensively washed and TMB reagent is added for signal development. The magnitude of absorbance for the developed color is proportional to the quantity of CRBN protein. Learn more about your ELISA kit options here.

    *Antibodies in this kit are custom formulations specific to kit.

    Protocol

    Specificity / Sensitivity

    The PathScan® RP CRBN Sandwich ELISA Kit detects endogenous levels of CRBN protein. The kit sensitivity is shown in Figure 1. This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.

    Species Reactivity:

    Human, Mouse, Rat

    Background

    CRBN/Cereblon, a substrate receptor for the CRL4 E3 ubiquitin ligase, was originally identified for its role in autosomal recessive nonsyndromic mental retardation (1). CRBN’s role in the regulation of the AMPK pathway has been linked to various human diseases, including cardiovascular disease and obesity, and its involvement in proteasomal degradation may be important in neuropsychiatric diseases (2). CRBN has also been shown to enhance the effects of immunomodulatory drugs (IMiDs) in multiple myeloma, and may be a predictive marker for therapy (2-4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    PathScan is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.